Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.

Trial Details

NCT ID
NCT04952272
Phase
PHASE1
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • CpG-ODN
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Solid advanced malignant tumors
  • Age between18 and 80 years
  • Life expectancy is greater than three months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →